JPRN-jRCT1071220082招募中Unknown
A multicenter, prospective, observational study investigating the efficacy and safety of polatuzumab vedotin plus R-CHP therapy in patients with previously untreated diffuse large B-cell lymphoma - POLASTAR
Kato Koji0 个研究点目标入组 500 人开始时间: 2022年12月23日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Patients with previously untreated diffuse large B-cell lymphoma
- •2. Patients who are scheduled to undergo polatuzumab vedotin (Pola) plus R-CHP therapy as medical practice based on the latest package insert of Pola
- •3. Patients who have received a sufficient explanation about the content of this study, have provided voluntary written informed consent from themselves, and are able to comply with the requirements of the study protocol
- •4. Patients aged 18 years or older at the time of obtaining informed consent
排除标准
- •Patients judged inappropriate for participation in this study by the site-investigator or sub-investigator
研究者
相似试验
已完成
不适用
A multicenter, prospective, observational study for the association serum pancreatic enzyme level and CT image findings in post-ERCP pancreatitisPost-ERCP pancreatitisJPRN-UMIN000024814Department of Gastroenterology, Kyoto Second Red Cross Hospital5,000
已完成
不适用
A multicenter, prospective, observational study for the incidence and high risk factor of post-ERCP pancreatitisPost-ERCP pancreatitisJPRN-UMIN000024813Department of Gastroenterology, Kyoto Second Red Cross Hospital5,000
招募中
Unknown
A multicenter, prospective, observational study for the control of delayed chemotherapy-induced nausea and vomiting for upper gastrointestinal cancerJPRN-UMIN000052322agoya University135
已完成
不适用
A prospective, multi-centre observational study in patients admitted to intensive care to estimate daily sodium balanceACTRN12612000046808Shailesh Bihari50
已完成
4 期
A Prospective, Multicenter, Observational Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated with Ixazomib plus Lenalidomide and DexamethasoneRelapsed and/or Refractory Multiple MyelomaJPRN-UMIN000031216Takeda Pharmaceutical Company Limited300